A poll conducted by the American Society of Health-System Pharmacists showed that 33% of 131 respondents reported that their supply of remdesivir was insufficient to treat all patients with COVID-19 infections eligible for the drug. The survey also found that 16% said they still had supplies of dexamethasone but these were only sufficient for less than seven days.
Poll: Some hospitals experiencing remdesivir shortages
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.